Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

2.240 -0.090 (-3.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts
Via Benzinga
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Autolus Therapeutics's Earnings Outlook
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Crude Oil Gains 1%; GameStop Shares Plunge
Via Benzinga
Exposures Fossil Fuels
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
From Autolus Therapeutics plc
Via GlobeNewswire
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.